FRAZIER MANAGEMENT LLC - Q2 2021 holdings

$1.08 Billion is the total value of FRAZIER MANAGEMENT LLC's 34 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 27.3% .

 Value Shares↓ Weighting
ARQT SellARCUTIS BIOTHERAPEUTICS INC$230,170,000
-24.5%
8,434,232
-20.0%
21.23%
-13.2%
TBIO SellTRANSLATE BIO INC$57,360,000
+59.4%
2,082,789
-4.6%
5.29%
+83.2%
KRYS SellKRYSTAL BIOTECH INC$53,576,000
-22.3%
787,876
-12.0%
4.94%
-10.7%
TARS SellTARSUS PHARMACEUTICALS INC$41,069,000
-33.5%
1,417,157
-26.1%
3.79%
-23.6%
SNDX SellSYNDAX PHARMACEUTICALS INC$20,400,000
-36.4%
1,188,135
-17.2%
1.88%
-26.9%
ACRS SellACLARIS THERAPEUTICS INC$6,510,000
-62.9%
370,733
-46.7%
0.60%
-57.4%
APTX SellAPTINYX INC$5,330,000
-44.3%
1,883,244
-41.0%
0.49%
-35.9%
IMVT SellIMMUNOVANT INC$2,685,000
-67.0%
254,000
-50.0%
0.25%
-62.1%
ITRM ExitITERUM THERAPEUTICS PLC$0-1,538,316
-100.0%
-0.17%
CRDF ExitCARDIFF ONCOLOGY INC$0-293,500
-100.0%
-0.22%
ADVM ExitADVERUM BIOTECHNOLOGIES INC$0-1,437,028
-100.0%
-1.14%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2021-08-11
Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
COLLEGIUM PHARMACEUTICAL INC21Q4 202037.0%
ANAPTYSBIO INC20Q4 202163.7%
CIDARA THERAPEUTICS INC20Q3 202017.2%
IOVANCE BIOTHERAPEUTICS INC19Q4 202113.7%
ALLENA PHARMACEUTICALS INC18Q1 202211.9%
ALPINE IMMUNE SCIENCES INC18Q4 20219.1%
APTINYX INC15Q4 202116.9%
KRYSTAL BIOTECH INC14Q4 20219.7%
GRITSTONE ONCOLOGY INC14Q4 20218.2%
SIERRA ONCOLOGY INC12Q4 20196.6%

View FRAZIER MANAGEMENT LLC's complete holdings history.

Latest filings
TypeFiled
13F-HR2022-11-14
13F-HR2022-08-10
13F-HR2022-05-13
13F-HR2022-02-08
13F-HR2021-11-12
13F-HR2021-08-11
13F-HR2021-05-12
13F-HR2021-02-11
13F-HR2020-11-12
13F-HR2020-08-04

View FRAZIER MANAGEMENT LLC's complete filings history.

Compare quarters

Export FRAZIER MANAGEMENT LLC's holdings